Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
Addex's Janssen-partnered epilepsy drug fails phase 2 trial
Addex’s run of bad luck in the clinic shows no sign of ending, with its Janssen-licensed epilepsy drug failing to reduce the occurrence of seizures.
James Waldron
Apr 29, 2024 8:44am
Xaira, Anthos, CureVac & more—Chutes & Ladders
Apr 26, 2024 8:30am
Cidara regains rights to flu med from Janssen, divests Rezzayo
Apr 24, 2024 4:05pm
As pharma eyes shiny obesity drugs, Vertex tops orphan drug list
Apr 24, 2024 12:01am
Recursion, Canaan, Metsera and more—Chutes & Ladders
Apr 19, 2024 8:30am
J&J CEO says M&A strategy to 'continue' after medtech megadeals
Apr 16, 2024 1:42pm